Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Change In Receivables : $0.61 Mil (TTM As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Change In Receivables?

Parnell Pharmaceuticals Holdings's change in receivables for the quarter that ended in Dec. 2018 was $0.61 Mil. It means Parnell Pharmaceuticals Holdings's Accounts Receivable declined by $0.61 Mil from Dec. 2017 to Dec. 2018 .

Parnell Pharmaceuticals Holdings's change in receivables for the fiscal year that ended in Dec. 2018 was $0.61 Mil. It means Parnell Pharmaceuticals Holdings's Accounts Receivable declined by $0.61 Mil from Dec. 2017 to Dec. 2018 .

Parnell Pharmaceuticals Holdings's Accounts Receivable for the quarter that ended in Dec. 2018 was $1.20 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Parnell Pharmaceuticals Holdings's Days Sales Outstanding for the six months ended in Dec. 2018 was 11.54.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Parnell Pharmaceuticals Holdings's liquidation value for the six months ended in Dec. 2018 was $-32.08 Mil.

Parnell Pharmaceuticals Holdings Change In Receivables Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Change In Receivables Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

Change In Receivables

Get a 7-Day Free Trial

-0.27

-0.37

2.30

3.38

0.61

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
Change In Receivables	Get a 7-Day Free Trial			-0.27	-0.37	2.30	3.38	0.61

Parnell Pharmaceuticals Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2018 was $0.61 Mil.

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Parnell Pharmaceuticals Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2018 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.203	/	19.031	*	91
=	11.54

2. In Ben Graham's calculation of liquidation value, Parnell Pharmaceuticals Holdings's accounts receivable are only considered to be worth 75% of book value:

Parnell Pharmaceuticals Holdings's liquidation value for the quarter that ended in Dec. 2018 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.155	-	37.285	+	0.75 * 1.203	+	0.5 * 2.29
=	-32.08

Parnell Pharmaceuticals Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.